Welcome to our dedicated page for ALX ONCOLOGY HOLDINGS SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ALX Oncology Holdings Inc. filings document a clinical-stage biotechnology issuer focused on cancer therapeutics and its Nasdaq-listed common stock. Recent 8-K reports furnish quarterly and annual financial results, corporate updates, clinical data releases for evorpacept and ALX2004, preliminary cash and investment information, and capital-structure disclosures tied to common stock and pre-funded warrant financing.
Proxy and governance filings describe board matters, executive compensation, equity awards, and shareholder voting items. Other material-event reports cover officer appointments, employment and compensatory arrangements, and amendments to the 2025 Inducement Equity Incentive Plan under Nasdaq inducement award rules.
BlackRock, Inc. filed a Schedule 13G reporting passive ownership of common stock of ALX Oncology Holdings Inc. BlackRock and its reporting business units beneficially own 7,327,850 ALXO shares, representing 5.4% of the outstanding common stock as of the filing.
BlackRock reports sole voting power over 7,231,560 shares and sole dispositive power over 7,327,850 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of ALXO’s outstanding common shares.
ALX Oncology Holdings SVP Shelly Wong reported an open-market sale of 1,404 shares of Common Stock at a weighted average price of $2.04 per share. According to the filing, the shares were sold to satisfy her tax obligations related to vesting of restricted stock units.
After this transaction, she directly holds 88,401 shares, which includes 3,000 shares acquired under the company’s employee stock purchase plan on June 30, 2026.
ALX Oncology Holdings Inc. reported a planned leadership transition at the board level. Corey Goodman, Ph.D., co-founder and long-time Chairman, resigned from the board and all its committees effective June 29, 2026, citing personal reasons and no disagreements with the company.
The board appointed existing independent director Scott Garland as Chairman effective the same date and named Michael Listgarten as General Counsel. Committee memberships were updated, with Rekha Hemrajani chairing Audit, Chris Takimoto chairing Compensation, and Daniel J. Curran chairing Corporate Governance and Nominating, reflecting a refreshed governance structure.
ALX Oncology Holdings Inc. entered into a new secured multi-tranche term loan facility of up to $50,000,000 with HSBC Ventures USA Inc. on June 25, 2026. The company drew $10,000,000 at closing to refinance its prior Oxford Finance and Silicon Valley Bank loan and pay fees, with remaining proceeds available for general corporate purposes.
An additional $20,000,000 is available to draw through June 30, 2028, with a further $10,000,000 tied to achieving positive data milestones in the Phase 2 ASPEN-09 study of Evorpacept and positive safety data in the Phase 1 study of ALX2004. A final $10,000,000 may be provided at the lender’s sole discretion.
The loans mature on June 1, 2030 and bear a floating interest rate equal to the greater of the Prime Rate or 6.0%, with amortization beginning July 1, 2028 or, if an Interest Only Milestone Event occurs, July 1, 2029. The facility is secured by substantially all assets (with a negative pledge on intellectual property) and includes customary covenants and events of default that could accelerate repayment if breached.
ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 10, 2026. Stockholders elected Class II directors Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P. to serve until the 2029 annual meeting, each continuing until a successor is elected and qualified.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, as described in the proxy statement. In addition, they ratified the appointment of KPMG LLP as ALX Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
ALX Oncology Holdings Inc. investors affiliated with Lightstone Ventures filed Amendment No. 3 to update their ownership in the company’s common stock. The group now beneficially owns 2,942,525 shares, representing 2.2% of the common stock, based on 134,562,917 shares outstanding as of May 1, 2026.
The filing explains that the group ceased to be beneficial owners of more than five percent of ALX Oncology’s common stock on or about February 2, 2026. This change resulted from dilution due to the issuer’s issuance of additional shares, not from any purchases or sales by the reporting persons, and no transactions occurred in the prior sixty days.
Redmile Group, LLC and related filers reported beneficial ownership of ALX Oncology common stock. The filing states Redmile Group and Jeremy C. Green beneficially own 9,214,188 shares representing 6.8%, and Redmile Biopharma Investments III, L.P. owns 5,267,838 shares representing 3.9%. The percentages are calculated using 134,540,741 shares outstanding as of March 31, 2026 plus 1,250,000 shares issuable upon exercise of warrants. The filing notes the Warrants are subject to a 9.99% beneficial ownership limitation and that Redmile and Mr. Green disclaim beneficial ownership except to the extent of any pecuniary interest.
ALX Oncology Holdings Inc has a Schedule 13G/A amendment reporting that HBM Healthcare Investments (Cayman) Ltd. beneficially owns 8,590,692 shares of common stock, representing approximately 6.5% of the outstanding common stock. The filing states this ownership is calculated using 131,608,278 shares outstanding as of March 2, 2026. Voting and investment power over these shares is exercised by the reporting person’s board of directors, and the amendment is signed by Jean-Marc LeSieur on May 15, 2026.
ALX Oncology Holdings Inc. reported a narrower net loss of $17.9 million for the three months ended March 31, 2026, compared with $30.8 million a year earlier, as it reduced spending while advancing its cancer pipeline.
Research and development expenses fell to $13.6 million and general and administrative costs to $5.4 million, largely due to a 2025 workforce reduction and pipeline prioritization. The company remains a clinical‑stage biotech focused on its CD47 blocker evorpacept and EGFR‑targeted ADC ALX2004, with multiple ongoing and planned trials in solid tumors and blood cancers.
ALX Oncology strengthened its balance sheet through a February 2026 equity financing, ending the quarter with $169.1 million in cash, cash equivalents and investments and an accumulated deficit of $740.7 million. Management expects these resources to fund operations for at least 12 months while it continues development and regulatory activities.
ALX Oncology Holdings Inc. reported first quarter 2026 results showing a significantly narrower loss while advancing its cancer pipeline. GAAP net loss was $17.9 million, or $0.17 per share, compared with $30.8 million, or $0.58 per share, a year earlier. Non-GAAP net loss improved to $15.4 million from $25.5 million.
Research and development expenses fell to $13.6 million from $23.9 million, and general and administrative costs declined to $5.4 million from $7.9 million, mainly due to prior workforce reductions and pipeline prioritization. Cash, cash equivalents and investments totaled $169.1 million as of March 31, 2026, and the company expects this to fund operations through the first half of 2028.
Clinically, exploratory Phase 1b/2 data for CD47-inhibitor evorpacept plus zanidatamab in heavily pre-treated HER2-positive metastatic breast cancer showed a confirmed objective response rate of 60% and median progression-free survival of 8.3 months in centrally confirmed HER2-positive patients. All patients with HER2-positive disease and high CD47 expression responded, with a median duration of response of 20.2 months. The Phase 2 ASPEN-09-Breast trial remains on track for topline data in mid-2027, and the Phase 1 trial of EGFR-targeted ADC ALX2004 continues toward safety data in the second half of 2026.